Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Another Covid vax deal for Oz?

Posted 19 January 2020 PM

Australia seems to have its eye on the single-dose Johnson & Johnson COVID-19 vaccine, with confirmation from the company's pharmaceutical division Janssen that it is working in "close collaboration" with the TGA to gain provisional registration.

J&J is in the final stages of data analysis for its phase 3 trial with the release of its efficacy numbers expected "very soon" in the words of CEO Alex Gorsky.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
How not to reform the PBAC
In the face of deep change, is piecemeal enough?
Approvals Action
New registrations for seizures and HIV
Eisai and ViiV add to their core franchises
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas